Get the Stockscreener App
31.35
0.06%
-0.02
After Hours:
31.38
0.03
+0.10%
Catalyst Pharmaceuticals Inc stock is traded at $31.35, with a volume of 1.77M.
It is down -0.06% in the last 24 hours and up +0.55% over the past month.
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.
See More
Previous Close:
$31.37
Open:
$31.37
24h Volume:
1.77M
Relative Volume:
0.86
Market Cap:
$3.84B
Revenue:
$596.96M
Net Income/Loss:
$221.32M
P/E Ratio:
18.02
EPS:
1.7397
Net Cash Flow:
$208.13M
1W Performance:
+0.03%
1M Performance:
+0.55%
6M Performance:
+29.60%
1Y Performance:
+32.45%
1-Day Range:
$31.34
$31.38
1-Week Range:
$31.33
$31.39
52-Week Range:
$19.05
$32.56
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
Name
Catalyst Pharmaceuticals Inc
Sector
Industry
Phone
(305) 529-2522
Address
355 ALHAMBRA CIRCLE, CORAL GABLES
Compare CPRX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CPRX
Catalyst Pharmaceuticals Inc
|
31.35 | 3.84B | 596.96M | 221.32M | 208.13M | 1.7397 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-04-25 | Initiated | Robert W. Baird | Outperform |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Mar-14-24 | Initiated | Citigroup | Buy |
| Mar-07-24 | Initiated | BofA Securities | Buy |
| Dec-21-23 | Initiated | Oppenheimer | Outperform |
| Aug-24-22 | Downgrade | ROTH Capital | Buy → Neutral |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-07-18 | Resumed | Piper Jaffray | Overweight |
| Oct-05-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Apr-26-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Sep-30-14 | Reiterated | ROTH Capital | Buy |
| Sep-16-14 | Reiterated | ROTH Capital | Buy |
| Sep-15-14 | Reiterated | H.C. Wainwright | Buy |
| Oct-21-13 | Reiterated | Aegis Capital | Buy |
| Sep-24-13 | Initiated | Maxim Group | Buy |
| Sep-06-13 | Reiterated | Aegis Capital | Buy |
| Apr-18-13 | Initiated | Aegis Capital | Buy |
| Aug-27-12 | Upgrade | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| Oct-01-09 | Upgrade | Merriman | Sell → Neutral |
| May-29-09 | Downgrade | Hapoalim | Neutral → Underperform |
| May-29-09 | Downgrade | Merriman Curhan Ford | Buy → Sell |
| Dec-15-08 | Initiated | Merriman Curhan Ford | Buy |
| Nov-28-07 | Initiated | Rodman & Renshaw | Mkt Outperform |
| Jan-31-07 | Initiated | Stifel Nicolaus | Buy |
| Jan-05-07 | Initiated | First Albany | Buy |
View All
Catalyst Pharmaceuticals Inc Stock (CPRX) Latest News
The Technical Signals Behind (CPRX) That Institutions Follow - Stock Traders Daily
Angelini Pharma to buy Catalyst in deal worth $4.1 billion - MSN
HC Wainwright & Co. Downgrades Catalyst Pharmaceuticals (CPRX) - MSN
Catalyst Investor Sues Over Proposed $4.1B Angelini Buyout - Law360
Catalyst (CPRX) up 0.6% since last earnings report: Can it continue? - MSN
Catalyst (CPRX) Up 0.6% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Angelini Pharma to buy Catalyst (CPRX) for $31.50 per share; virtual vote July 8 - Stock Titan
Catalyst Pharmaceuticals (CPRX) CMO gets 3,052 shares, 743 withheld for tax - Stock Titan
Dakota Review Highlights Broad-Based Strength in May 2026 Private Markets Activity - TipRanks
Homogeneous Catalyst Market Growth Outlook to 2035: Trends, Drivers, and Regional AnalysisNews and Statistics - IndexBox
Precision Trading with Catalyst Pharmaceuticals Inc. (CPRX) Risk Zones - Stock Traders Daily
CPRX PE Ratio & Valuation, Is CPRX Overvalued - Intellectia AI
Opportunities in the Oncology Market: Positioning for the Next Billion-Dollar Catalyst with BioNTech, Vidac Pharma, and Pfizer - news.financial
CPRX Stock Price, Quote & Chart | CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) - ChartMill
D.R. Horton Inc. (DHI) Q1 2026 Earnings: Slight EPS Beat Amid Mixed Housing ConditionsEarnings Growth Analysis - thelegaladvocate.com
H.C. Wainwright Maintains Catalyst Pharmaceuticals(CPRX.US) With Hold Rating, Maintains Target Price $31.5 - Moomoo
Catalyst (CPRX) to be acquired by Angelini Pharma for $31.50 per share (cash) - Stock Titan
H.C. Wainwright Downgrades Catalyst Pharmaceuticals(CPRX.US) to Hold Rating, Cuts Target Price to $31.5 - Moomoo
Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-Term - Yahoo Finance
CPRX Technical Analysis | Trend, Signals & Chart Patterns | CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) - ChartMill
Why Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-Term - Yahoo Finance
Technical Reactions to CPRX Trends in Macro Strategies - Stock Traders Daily
Angelini Buyout And FIRDAPSE Settlement Reframe Catalyst Pharmaceuticals Story - Yahoo Finance
Third Avenue Management's Catalyst Pharmaceuticals Inc(CPRX) Holding History - GuruFocus
Catalyst Pharmaceuticals Q1 earnings beat, Firdapse revenues rise Y/Y - MSN
Angelini Buyout And Firdapse Settlement Reframe Catalyst Pharmaceuticals Story - Sahm
Catalyst Pharmaceuticals, Inc.Common Stock (NQ: CPRX - FinancialContent
Angelini Interest Puts Catalyst Pharmaceuticals Rare Disease Value In Focus - Sahm
Catalyst Pharmaceuticals: Angelini Deal Caps A Potentially Better Story (NASDAQ:CPRX) - Seeking Alpha
CPRX SWOT Analysis: Strong Financials Amidst Market Challenges R - GuruFocus
Catalyst Pharmaceuticals Q1 Earnings Beat, Firdapse Revenues Rise Y/Y - Yahoo Finance
Trading the Move, Not the Narrative: (CPRX) Edition - Stock Traders Daily
Catalyst Pharmaceuticals earnings beat by $0.06, revenue topped estimates - Investing.com Canada
Catalyst Pharmaceuticals (CPRX) Announces Suspension of Guidance Updates - GuruFocus
Catalyst Pharmaceuticals, Inc. Q1 2026 earnings preview - MSN
CPRX Reports Impressive Q1 Revenue Growth - GuruFocus
Catalyst Pharma Reports Higher Revenue, Suspends Earnings Guidance - TipRanks
Catalyst Pharmaceutical (CPRX) Surpasses Q1 Earnings and Revenue Estimates - Yahoo Finance
Catalyst Pharmaceuticals 1Q EPS 50c >CPRX - Moomoo
Profit rises at Catalyst Pharmaceuticals (NASDAQ: CPRX) on Q1 2026 results - Stock Titan
Catalyst Pharmaceuticals Q1 Adjusted Earnings, Revenue Rise - marketscreener.com
Catalyst Pharmaceuticals Reports First Quarter 2026 Financial Results - The Manila Times
Earnings Flash (CPRX) Catalyst Pharmaceuticals, Inc. Reports Q1 Revenue $149.4M, vs. FactSet Est of $149.5M - marketscreener.com
Earnings Flash (CPRX) Catalyst Pharmaceuticals, Inc. Posts Q1 Adjusted EPS $0.79 per Share, vs. FactSet Est of $0.65 - marketscreener.com
Earnings Flash (CPRX) Catalyst Pharmaceuticals, Inc. Posts Q1 Adjusted EPS $0.79 per Share, Vs. FactSet Est of $0.65 - Moomoo
BRIEF-Catalyst Pharmaceuticals Q1 Revenue USD 149.4 Million Vs. IBES Estimate USD 148.2 Million - TradingView
Catalyst Pharma (NASDAQ: CPRX) posts Q1 profit ahead of Angelini deal - Stock Titan
Catalyst Pharmaceuticals Inc Stock (CPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Catalyst Pharmaceuticals Inc Stock (CPRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Harper Molly | Director |
Dec 12 '25 |
Sale |
23.25 |
26,746 |
621,920 |
2,360 |
1.27%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):